Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study

Abstract Background The integration of transarterial chemoembolization (TACE) with systemic therapy has demonstrated improved survival outcomes in patients with unresectable hepatocellular carcinoma (HCC). However, there is limited evidence evaluating the combination of TACE with the systemic regime...

Full description

Bibliographic Details

Published in:	Cancer Immunology, Immunotherapy
Main Authors:	Lingzhan Meng, Hu Li, Yingjie Ji, Peng Yu, Zizheng Wang, Li Cao, Bin Shi, Yanling Shao, Jin Yan, Yinjie Gao, Zhenyu Zhu
Format:	Article
Language:	English
Published:	Springer 2024-11-01
Subjects:	Combination therapy Hepatocellular carcinoma Lenvatinib Sintilimab Transarterial chemoembolization (TACE)
Online Access:	https://doi.org/10.1007/s00262-024-03857-5